Erschienen in:
15.02.2022 | Short Communication
Liver Growth and Portal Hypertension Improvement After Percutaneous Recanalization of Chronic Portal Vein Thrombosis in Non-Cirrhotic Participants
verfasst von:
Raphael Braz Levigard, Henrique Salas, Henrique Serrão, Felipe Diniz, Cristiane Alves Villela Nogueira, Alicia Araújo de Oliveira, Nathalie Carvalho Leite, Marcia Ladeira, Maria Chiara Chindamo, Gustavo Pereira
Erschienen in:
CardioVascular and Interventional Radiology
|
Ausgabe 5/2022
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To evaluate liver function improvement and volume gain after percutaneous recanalization of chronic portal vein thrombosis (PVT) in non-cirrhotic patients.
Materials and Methods
In this retrospective study, five non-cirrhotic participants between 21 and 67 years old with secondary chronic PVT (4–21 years from diagnose) were submitted to percutaneous portal vein recanalization, followed by varices and shunts embolization.
Results
After a mean of 12.6 months, all portal veins remained patent and there was complete resolution of portal hypertension (PH) symptoms in all participants. There was a significant increase in liver volume of 39.8 ± 19.0% (p = 0.042), platelets count of 53120 ± 20188/μl (p = 0.042), and a significant decrease in total bilirubin levels from 1.04 ± 0.23 mg/dL to 0.51 ± 0.09 mg/dL (p = 0.043). We also found a non-significant increase in albumin levels from 3.88 ± 0.39 g/dL to 4.38 ± 0.27 g/dL (p = 0.078) and decrease in spleen diameter from 16.88 ± 4.03 cm to 14.15 ± 2.72 cm (p = 0.068).
Discussion
In this retrospective study, even with a small number of participants, we were capable of showing a median of 39.8% increase in liver volume, laboratorial liver function improvement, platelets count and resolution of PH symptoms, including gastroesophageal varices disappearance after portal vein recanalization followed by shunt embolization.
Conclusion
In this small series of cases, recanalization of chronic PVT in non-cirrhotic participants was feasible, successful and safe despite the prolonged time of occlusion. This is a new and promising approaching to an old and still challenging disease.